外高桥集团启动脑机接口伙伴计划

Core Insights - The Waigaoqiao Group has launched the "Brain-Computer Interface Innovation Development Partnership Program" to enhance its position in the brain-computer interface (BCI) sector, aiming to become a preferred "landing point" and "accelerator" for BCI innovations [1] Group 1: Partnership Program Details - The partnership program aims to unite enterprises, hospitals, and government departments to collaboratively build an innovative ecosystem that addresses bottlenecks in clinical transformation, cross-border data, and market access for BCI technology [1] - Participating companies will receive the "Waigaoqiao Brain-Computer Interface Product Service Package," which includes comprehensive support from cross-border R&D pilot projects to clinical approval acceleration and market expansion [1] - Initial participants will also benefit from preferential support in terms of space and guidance on relevant industrial policies provided by the Waigaoqiao Group [2] Group 2: Industry Context and Developments - The BCI sector is on the verge of transitioning from laboratory research to clinical application, with companies aiming to establish a full-service capability from R&D to market entry to capture future industry opportunities [2] - Recently, Ladder Medical's "Implantable Wireless Brain-Computer Interface System" has entered the special review process by the National Medical Products Administration, marking a significant milestone for invasive BCI products in China [2] - Ladder Medical has developed the world's smallest brain-controlled implant and is progressing towards full domestic production, collaborating with Fudan University Huashan Hospital for prospective clinical trials [2] Group 3: Strategic Advantages - The development of BCI technology relies heavily on interdisciplinary collaboration, cross-border R&D, and international cooperation, which aligns with Waigaoqiao's strategic advantages [3] - Waigaoqiao offers "bonded R&D" policy functions and serves as a hub connecting domestic and international markets, facilitating data cross-border and personnel movement [3] - The company provides comprehensive policy adaptation services for BCI enterprises, covering the entire process from clinical trials to overseas registration [4]